Put Contract Details: The $75.00 put contract has a bid of 65 cents, allowing an investor to purchase ILMN stock at that price while collecting a premium, effectively lowering the cost basis to $74.35.
Potential Outcomes for Put Contract: With an 89% chance of expiring worthless, this strategy could yield a 0.87% return on cash commitment or 3.47% annualized, referred to as YieldBoost.
Call Contract Overview: The $105.00 call contract has a bid of $6.70, offering a potential total return of 7.96% if exercised, while also presenting a 47% chance of expiring worthless, allowing investors to retain shares and premium collected.
Volatility Insights: Implied volatility for the put contract is 61%, while for the call it is 43%, with actual trailing twelve-month volatility calculated at 42%.
ILMN
$131.56+Infinity%1D
Analyst Views on ILMN
Wall Street analysts forecast ILMN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ILMN is 117.25 USD with a low forecast of 80.00 USD and a high forecast of 195.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast ILMN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ILMN is 117.25 USD with a low forecast of 80.00 USD and a high forecast of 195.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
5 Hold
3 Sell
Hold
Current: 134.920
Low
80.00
Averages
117.25
High
195.00
Current: 134.920
Low
80.00
Averages
117.25
High
195.00
JPMorgan
Casey Woodring
Neutral
maintain
$105 -> $130
2025-12-15
New
Reason
JPMorgan
Casey Woodring
Price Target
$105 -> $130
2025-12-15
New
maintain
Neutral
Reason
JPMorgan analyst Casey Woodring raised the firm's price target on Illumina to $130 from $105 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics group.
Barclays
Underweight
maintain
$100 -> $110
2025-12-15
New
Reason
Barclays
Price Target
$100 -> $110
2025-12-15
New
maintain
Underweight
Reason
Barclays raised the firm's price target on Illumina to $110 from $100 and keeps an Underweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.
Piper Sandler
NULL -> Overweight
maintain
$185 -> $195
2025-11-10
Reason
Piper Sandler
Price Target
$185 -> $195
2025-11-10
maintain
NULL -> Overweight
Reason
Piper Sandler raised the firm's price target on Illumina to $195 from $185 following quarterly results. The firm keeps an Overweight rating on the shares.
JPMorgan
Neutral
maintain
$100 -> $105
2025-10-31
Reason
JPMorgan
Price Target
$100 -> $105
2025-10-31
maintain
Neutral
Reason
JPMorgan raised the firm's price target on Illumina to $105 from $100 and keeps a Neutral rating on the shares. The company reported a "beat and raise" Q3, the analyst tells investors in a research note.
About ILMN
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
